Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study.
Giant cell arteritis
Hematologic neoplasms
Malignancy
Neoplasms
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
14
11
2018
accepted:
18
12
2018
pubmed:
9
1
2019
medline:
4
12
2019
entrez:
9
1
2019
Statut:
ppublish
Résumé
Some studies suggest that there is an increased risk of malignancies in giant cell arteritis (GCA). We aimed to describe the clinical characteristics and outcomes of GCA patients with concomitant malignancy and compare them to a GCA control group. Patients with a diagnosis of GCA and malignancy and with a maximal delay of 12 months between both diagnoses were retrospectively included in this study and compared to a control group of age-matched (3:1) patients from a multicenter cohort of GCA patients. Forty-nine observations were collected (median age 76 years). Malignancies comprised 33 (67%) solid neoplasms and 16 (33%) clonal hematologic disorders. No over-representation of a particular type of malignancy was observed. Diagnosis of GCA and malignancy was synchronous in 7 (14%) patients, while malignancy succeeded GCA in 29 (59%) patients. Malignancy was fortuitously diagnosed based on abnormalities observed in laboratory tests in 26 patients, based on imaging in 14 patients, and based on symptoms or clinical examination in the nine remaining patients. Two patients had a concomitant relapse of both conditions. When compared to the control group, patients with concomitant GCA and malignancy were more frequently male (p < 0.001), with an altered general state (p < 0.001), and polymyalgia rheumatica (p < 0.01). This study does not indicate an over-representation of any particular type of malignancy in GCA patients. Initial follow-up dictated by vasculitis may have led to an early identification of malignancy. Nevertheless, GCA male patients with an altered general state and polymyalgia rheumatica might more frequently show concomitant malignancies.
Identifiants
pubmed: 30617596
doi: 10.1007/s10067-018-04407-y
pii: 10.1007/s10067-018-04407-y
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1243-1249Références
Weyand CM, Goronzy JJ (2014) Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 371:50–57
doi: 10.1056/NEJMcp1214825
pubmed: 24988557
pmcid: 24988557
Buttgereit F, Dejaco C, Matteson EL, Dasgupta B (2016) Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 315:2442
doi: 10.1001/jama.2016.5444
pubmed: 27299619
Samson M, Corbera-Bellalta M, Audia S, Planas-Rigol E, Martin L, Cid MC, Bonnotte B (2017) Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev 16:833–844
doi: 10.1016/j.autrev.2017.05.014
pubmed: 28564617
Ramadan SM, Fouad TM, Summa V, Hasan SK, Lo-Coco F (2012) Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica 97:805–817
doi: 10.3324/haematol.2011.056283
pubmed: 22180424
pmcid: 3366644
Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR (2010) Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 95:1216–1220
doi: 10.3324/haematol.2009.020412
pubmed: 20053870
pmcid: 2895049
Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, ParIès J, Stirnemann J, Morin AS, Gatfosse M, Hanslik T, Belmatoug N, Blétry O, Cevallos R, Delevaux I, Fisher E, Hayem G, Kaplan G, le Hello C, Mouthon L, Larroche C, Lemaire V, Piette AM, Piette JC, Ponge T, Puechal X, Rossert J, Sarrot-Reynauld F, Sicard D, Ziza JM, Kahn MF, Guillevin L (2007) Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 57:1473–1480
Agha A, Bateman H, Sterrett A, Valeriano-Marcet J (2012) Myelodysplasia and malignancy-associated vasculitis. Curr Rheumatol Rep 14:526–531
doi: 10.1007/s11926-012-0281-3
pubmed: 22821200
Hutson TE, Hoffman GS (2000) Temporal concurrence of vasculitis and cancer: a report of 12 cases. Arthritis Care Res 13:417–423
doi: 10.1002/1529-0131(200012)13:6<417::AID-ART13>3.0.CO;2-T
pubmed: 14635319
Kurzrock R, Cohen PR (1993) Vasculitis and cancer. Clin Dermatol 11:175–187
doi: 10.1016/0738-081X(93)90115-S
pubmed: 8339194
Solans-Laque R, Bosch-Gil JA, Pérez-Bocanegra C et al (2008) Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol 35:294–304
pubmed: 18085729
Bellan M, Boggio E, Sola D, Gibbin A, Gualerzi A, Favretto S, Guaschino G, Bonometti R, Pedrazzoli R, Pirisi M, Sainaghi PP (2017) Association between rheumatic diseases and cancer: results from a clinical practice cohort study. Intern Emerg Med 12:621–627
doi: 10.1007/s11739-017-1626-8
pubmed: 28181122
Galland J, Kawski H, Guichard J-F, Maurier F (2017) Vascularite des gros vaisseaux et syndrome myélodysplasique : une association rare. Rev Med Interne 38:474–477
doi: 10.1016/j.revmed.2016.12.010
pubmed: 28094068
Yu K-H, Kuo C-F, Huang LH, Huang WK, See LC (2016) Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan. Medicine (Baltimore) 95:e3540
doi: 10.1097/MD.0000000000003540
Zurada JM, Ward KM, Grossman ME (2006) Henoch-Schönlein purpura associated with malignancy in adults. J Am Acad Dermatol 55:S65–S70
doi: 10.1016/j.jaad.2005.10.011
pubmed: 17052537
Hamidou MA, Derenne S, Audrain MA, Berthelot JM, Boumalassa A, Grolleau JY (2000) Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. Rheumatology (Oxford) 39:417–420
doi: 10.1093/rheumatology/39.4.417
Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W (1995) Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 91:403–408
doi: 10.1111/j.1365-2141.1995.tb05310.x
pubmed: 8547082
Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM (2004) Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology 43:626–632
de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Lévesque H, Hamidou M, Subra JF, Ifrah N, Belizna C (2011) Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken) 63:1188–1194
doi: 10.1002/acr.20504
Berthier S, Magy N, Gil H, Becker Schneider M, Vuitton DA, Dupond JL (2001) Myélodysplasies et maladies systémiques. Une association non fortuite. Rev Med Interne 22:428–432
doi: 10.1016/S0248-8663(01)00367-8
pubmed: 11402513
Jachiet V, Mekinian A, Carrat F, Grignano E, Retbi A, Boffa JJ, Ronco P, Rondeau E, Sellam J, Berenbaum F, Chazouillères O, Capron J, Alamowitch S, Chasset F, Frances C, Coppo P, Fain O, on behalf of French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON) (2018) Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. Leuk Lymphoma 59:1399–1405
doi: 10.1080/10428194.2017.1379075
pubmed: 28972423
Billström R, Johansson H, Johansson B, Mitelman F (1995) Immune-mediated complications in patients with myelodysplastic syndromes–clinical and cytogenetic features. Eur J Haematol 55:42–48
doi: 10.1111/j.1600-0609.1995.tb00231.x
pubmed: 7615049
Ustwani OA, Ford LA, Sait SJN, Block AMW, Barcos M, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Ambrus J Jr, Wetzler M (2013) Myelodysplastic syndromes and autoimmune diseases—case series and review of literature. Leuk Res 37:894–899
doi: 10.1016/j.leukres.2013.04.007
pubmed: 23692654
pmcid: 3699612
Liozon E, Loustaud-Ratti V, Soria P, Bezanahary H, Fauchais AL, Nadalon S, Rhaiem K, Ly K, Vidal É (2004) Disease associations in 250 patients with temporal (giant cell) arteritis. Presse Med 33:1304–1312
doi: 10.1016/S0755-4982(04)98914-2
pubmed: 15615235
Liozon E, Loustaud V, Fauchais A-L, Soria P, Ly K, Ouattara B, Rhaiem K, Nadalon S, Vidal E (2006) Concurrent temporal (giant cell) arteritis and malignancy: report of 20 patients with review of the literature. J Rheumatol 33:1606–1614
pubmed: 16832846
Mertens JCC, Willemsen G, Van Saase J et al (1995) Polymyalgia rheumatica and temporal arteritis: a retrospective study of 111 patients. Clin Rheumatol 14:650–655
doi: 10.1007/BF02207931
pubmed: 8608683
Gonzalez-Gay MA, Lopez-Diaz MJ, Martinez-Lado L, Peña-Sagredo JL, Lopez-Agreda H, Miranda-Filloy JA, Gonzalez-Juanatey C, Sanchez-Andrade A, Martin J, Llorca J (2007) Cancer in biopsy-proven giant cell arteritis. A population-based study. Semin Arthritis Rheum 37:156–163
doi: 10.1016/j.semarthrit.2007.03.006
pubmed: 17509668
Hill CL, Cole A, Rischmueller M, Dodd T, Coleman M, Tucker G, Roberts-Thomson P (2010) Risk of cancer in patients with biopsy-proven giant cell arteritis. Rheumatology 49:756–759
doi: 10.1093/rheumatology/kep409
pubmed: 20089693
Kermani TA, Schäfer VS, Crowson CS et al (2010) Malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthritis Care Res (Hoboken) 62:149–154
doi: 10.1002/art.27320
pmcid: 2874240
Ninan J, Nguyen A-M, Cole A et al (2011) Mortality in patients with biopsy-proven giant cell arteritis: a south Australian population-based study. J Rheumatol 38:2215–2217
doi: 10.3899/jrheum.101254
pubmed: 21844141
Lee YH, Song GG (2018) Overall and cause-specific mortality in giant cell arteritis: a meta-analysis. Z Rheumatol 77:946–951. https://doi.org/10.1007/s00393-018-0440-7
doi: 10.1007/s00393-018-0440-7
pubmed: 29557499
Bengtsson B, Malmvall B-E (1981) Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand 209:337–345
doi: 10.1111/j.0954-6820.1981.tb11604.x
pubmed: 7246269
von Knorring J, Somer T (1974) Malignancy in association with polymyalgia rheumatica and temporal arteritis. Scand J Rheumatol 3:129–135
doi: 10.3109/03009747409097138
Andersson R, Malmvall B-E, Bengtsson B (1986) Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 220:465–469
doi: 10.1111/j.0954-6820.1986.tb02796.x
pubmed: 3812030
Ji J, Liu X, Sundquist K, Sundquist J, Hemminki K (2010) Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology 49:1158–1163
doi: 10.1093/rheumatology/keq040
pubmed: 20299378
Ješe R, Rotar Ž, Tomšič M, Hočevar A (2018) Giant cell arteritis and malignancy-more than just a coincidence? J Clin Rheumatol 24:85–86. https://doi.org/10.1097/RHU.0000000000000697
doi: 10.1097/RHU.0000000000000697
pubmed: 29384830
Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT (2002) No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol 29:2143–2147
pubmed: 12375324
Ungprasert P, Sanguankeo A, Upala S, Knight EL (2014) Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis. Semin Arthritis Rheum 44:366–370
doi: 10.1016/j.semarthrit.2014.06.004
pubmed: 25074657
Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122–1128
doi: 10.1002/art.1780330810
pubmed: 2202311
Institut national du cancer (2018) Les cancers en France, édition 2017
Park HJ, Ranganathan P (2011) Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin N Am 37:593–606
doi: 10.1016/j.rdc.2011.09.002
Baslund B, Helleberg M, Faurschou M, Obel N (2015) Mortality in patients with giant cell arteritis. Rheumatology (Oxford) 54:139–143
doi: 10.1093/rheumatology/keu303
Aouba A, Gonzalez Chiappe S, Eb M, Delmas C, de Boysson H, Bienvenu B, Rey G, Mahr A (2018) Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980-2011). Rheumatology (Oxford) 57:1047–1055
doi: 10.1093/rheumatology/key028
Hamidou MA, El Kouri D, Audrain M, Grolleau JY (2001) Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia. Ann Rheum Dis 60:293–295
doi: 10.1136/ard.60.3.293
pubmed: 11171697
pmcid: 1753562
Podjasek JO, Wetter DA, Pittelkow MR, Wada DA (2012) Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009. J Am Acad Dermatol 66:e55–e65
doi: 10.1016/j.jaad.2010.09.732
pubmed: 21093106
Wolach O, Stone R (2016) Autoimmunity and inflammation in myelodysplastic syndromes. Acta Haematol 136:108–117
doi: 10.1159/000446062
pubmed: 27337745